BRPI1009637A2 - composto, composição e uso de um composto - Google Patents

composto, composição e uso de um composto

Info

Publication number
BRPI1009637A2
BRPI1009637A2 BRPI1009637-0A BRPI1009637A BRPI1009637A2 BR PI1009637 A2 BRPI1009637 A2 BR PI1009637A2 BR PI1009637 A BRPI1009637 A BR PI1009637A BR PI1009637 A2 BRPI1009637 A2 BR PI1009637A2
Authority
BR
Brazil
Prior art keywords
compound
composition
application
diseases
salts
Prior art date
Application number
BRPI1009637-0A
Other languages
English (en)
Inventor
A. Curry Matthew
D. Dorsey Bruce
J. Dugan Benjamin
E. Gingrich Diane
F. Mesaros Eugen
L. Milkiewics Karen
Original Assignee
Cephalon, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1009637(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon, Inc filed Critical Cephalon, Inc
Publication of BRPI1009637A2 publication Critical patent/BRPI1009637A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

composto, composição e uso de um composto este pedido refere-se a compostos da fórmula geral i e sais dos mesmos, em que x, r1a, r1b , r2 , r3 , r4 , e r5 são conforme definidos no presente documento. o pedido também se refere a métodos e composições de tratamento de transtornos ou doenças hiperproliferativos.
BRPI1009637-0A 2009-06-05 2010-06-04 composto, composição e uso de um composto BRPI1009637A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18453309P 2009-06-05 2009-06-05
US61/184,533 2009-06-05
PCT/US2010/037363 WO2010141796A2 (en) 2009-06-05 2010-06-04 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
BRPI1009637A2 true BRPI1009637A2 (pt) 2019-04-30

Family

ID=42985748

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009637-0A BRPI1009637A2 (pt) 2009-06-05 2010-06-04 composto, composição e uso de um composto

Country Status (14)

Country Link
US (2) US8501936B2 (pt)
EP (1) EP2438066A2 (pt)
JP (1) JP5684245B2 (pt)
KR (1) KR20120044966A (pt)
CN (1) CN102459258B (pt)
AU (1) AU2010254806C1 (pt)
BR (1) BRPI1009637A2 (pt)
CA (1) CA2763900A1 (pt)
CL (1) CL2011003082A1 (pt)
IL (1) IL216609A0 (pt)
MX (1) MX2011012961A (pt)
NZ (1) NZ597140A (pt)
TW (1) TWI500614B (pt)
WO (1) WO2010141796A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009259867A1 (en) * 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
RU2560153C2 (ru) 2008-06-20 2015-08-20 Дженентек, Инк. Триазолпиридиновые соединения, ингибирующие jak, и способы
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
KR20130110163A (ko) * 2010-08-27 2013-10-08 메르크 파텐트 게엠베하 트리아졸로피라진 유도체들
EP2648728B1 (en) * 2010-12-06 2016-04-27 Cephalon, Inc. Janus kinase 2 (jak2) inhibitor for the treatment of lupus
JP6046633B2 (ja) * 2010-12-06 2016-12-21 セファロン、インク． １，２，４−トリアゾロ［１，５ａ］ピリジン誘導体を用いた慢性炎症の治療
DK2675793T3 (en) 2011-02-17 2018-11-12 Cancer Therapeutics Crc Pty Ltd FAK INHIBITORS
EP2675794B1 (en) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
EP2714703B1 (en) * 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
KR20130091464A (ko) * 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
ES2674451T3 (es) * 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
HK1203948A1 (en) * 2012-03-07 2015-11-06 Merck Patent Gmbh Triazolopyrazine derivatives
MY177334A (en) * 2012-06-22 2020-09-12 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
NZ703020A (en) * 2012-07-10 2017-08-25 Bayer Pharma AG Method for preparing substituted triazolopyridines
US20150299796A1 (en) * 2012-07-27 2015-10-22 Alexander CAO Prediction of treatment response to jak/stat inhibitor
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
MA38884A1 (fr) * 2013-09-05 2017-06-30 Hoffmann La Roche Composé de triazolopyridine, compositions et procédés d'utilisation associés
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2016139212A1 (en) * 2015-03-04 2016-09-09 F. Hoffmann-La Roche Ag Triazolopyridine compounds and methods of use thereof
US11414413B2 (en) 2016-07-26 2022-08-16 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
JP7050761B2 (ja) * 2016-09-06 2022-04-08 エフ．ホフマン－ラ ロシュ アーゲー ８－（アゼチジン－１－イル）－［１，２，４］トリアゾロ［１，５－ａ］ピリジニル化合物、組成物及びその使用方法
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
EA039352B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
WO2020094363A1 (en) 2018-11-05 2020-05-14 Syngenta Participations Ag Pesticidally active azole-amide compounds
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
BR112021007421A2 (pt) 2018-12-06 2021-08-03 Daiichi Sankyo Company, Limited derivado de cicloalcano-1,3-diamina
AU2020257301B2 (en) 2019-04-18 2025-10-23 The Johns Hopkins University Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof
CN111057059B (zh) * 2019-11-25 2022-04-26 广东省测试分析研究所（中国广州分析测试中心） 一种苯并二四氢吡咯类化合物或其药学上可接受的盐、及其制备方法和应用
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023009708A1 (en) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2025073290A1 (en) * 2023-10-06 2025-04-10 Para Therapeutics, Inc. Vps4 inhibitors and methods of use thereof
WO2025240333A1 (en) * 2024-05-13 2025-11-20 The Texas A&M University System Jak3 targeted smart drugs and uses thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492696A (en) * 1989-04-14 1996-02-20 The Government Of The United States Of America As Represented By The Secretary Of The Navy Controlled release microstructures
US5651976A (en) * 1993-06-17 1997-07-29 The United States Of America As Represented By The Secretary Of The Navy Controlled release of active agents using inorganic tubules
US5705191A (en) * 1995-08-18 1998-01-06 The United States Of America As Represented By The Secretary Of The Navy Sustained delivery of active compounds from tubules, with rational control
US6936215B1 (en) * 1996-08-27 2005-08-30 The United States Of America As Represented By The Secretary Of The Navy Processing methodology for the rational control of bilayer numbers leading to high efficiency production of lipid microtubules
DE122009000052I2 (de) 1996-09-24 2009-12-31 Dow Agrosciences Llc N-((1,2,4)triazoloazinyl)benzolsulfonamid- und pyridinsulfonamidverbindungen und deren verwendung als herbizide
US6013206A (en) * 1998-05-18 2000-01-11 The United States Of America As Represented By The Secretary Of The Navy Process for the formation of high aspect ratio lipid microtubules
AU3724100A (en) * 1999-03-03 2000-09-21 United States Of America As Represented By The Secretary Of The Navy, The An efficient method for subsurface treatments, including squeeze treatments
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
CN1221552C (zh) 2000-11-03 2005-10-05 美国陶氏益农公司 用作除草剂的n－((1,2,4,)三唑并嗪基)噻吩磺酰胺化合物
BR0116216A (pt) 2000-12-15 2004-08-17 Vertex Pharma Inibidores de girase e seus usos
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
US7125476B2 (en) * 2003-01-30 2006-10-24 The United States Of America As Represented By The Secretary Of The Navy Microwave-attenuating composite materials, methods for preparing the same, intermediates for preparing the same, devices containing the same, methods of preparing such a device, and methods of attenuating microwaves
WO2005009348A2 (en) 2003-06-25 2005-02-03 Ariad Pharmaceuticals, Inc. Substituted purine derivatives
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
EP1778686B9 (en) 2004-08-12 2009-07-08 Pfizer Limited Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
US7400490B2 (en) * 2005-01-25 2008-07-15 Naturalnano Research, Inc. Ultracapacitors comprised of mineral microtubules
US20060257543A1 (en) 2005-02-04 2006-11-16 Catherine Tachdjian Molecules comprising linked organic moieties as flavor modifiers for comestible compositions
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP1832629B1 (en) * 2006-03-10 2016-03-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Corrosion inhibiting pigment comprising nanoreservoirs of corrosion inhibitor
CA2650976A1 (en) 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
MX2008015747A (es) * 2006-06-06 2008-12-19 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa.
CA2654394A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
SG174086A1 (en) 2006-08-30 2011-09-29 Cellzome Ltd Triazole derivatives as kinase inhibitors
AU2007307031B2 (en) 2006-10-11 2011-11-24 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
JP2010511018A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物
US20080248201A1 (en) * 2007-04-06 2008-10-09 Naturalnano Research, Inc. Polymeric coatings including nanoparticle filler
CN101772498A (zh) 2007-04-10 2010-07-07 H.隆德贝克有限公司 作为p2x7拮抗剂的杂芳基酰胺类似物
JP2010523725A (ja) 2007-04-16 2010-07-15 レオ ファーマ アクティーゼルスカブ 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
CA2689514C (en) 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
KR20100049073A (ko) 2007-07-18 2010-05-11 노파르티스 아게 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
WO2009027736A2 (en) 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
JP2010536917A (ja) 2007-08-31 2010-12-02 メルク セローノ ソシエテ アノニム トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009048474A1 (en) 2007-10-12 2009-04-16 Pharmacopeia, Inc. 2,7,9-substituted purinone derivatives for immunosuppression
SG186040A1 (en) 2007-11-27 2012-12-28 Cellzome Ltd Amino triazoles as pi3k inhibitors
US8445509B2 (en) 2008-05-08 2013-05-21 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
RU2560153C2 (ru) * 2008-06-20 2015-08-20 Дженентек, Инк. Триазолпиридиновые соединения, ингибирующие jak, и способы
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010018874A1 (en) 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
JP2010070503A (ja) 2008-09-19 2010-04-02 Daiichi Sankyo Co Ltd 抗真菌作用２−アミノトリアゾロピリジン誘導体
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
NZ593595A (en) 2008-12-19 2013-07-26 Leo Pharma As Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
KR20110116160A (ko) 2009-02-13 2011-10-25 포비어 파마수티칼스 카이네이스 저해제로서의 〔1,2,4〕트리아졸로〔1,5-ａ〕피리딘
PE20121511A1 (es) * 2010-01-15 2012-12-06 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa

Also Published As

Publication number Publication date
AU2010254806C1 (en) 2016-07-07
JP5684245B2 (ja) 2015-03-11
AU2010254806A1 (en) 2012-01-19
MX2011012961A (es) 2012-01-30
AU2010254806B2 (en) 2016-02-04
CA2763900A1 (en) 2010-12-09
WO2010141796A2 (en) 2010-12-09
CL2011003082A1 (es) 2012-06-08
WO2010141796A3 (en) 2012-02-16
JP2012528886A (ja) 2012-11-15
NZ597140A (en) 2014-01-31
TW201100421A (en) 2011-01-01
US8501936B2 (en) 2013-08-06
EP2438066A2 (en) 2012-04-11
US8633173B2 (en) 2014-01-21
US20130296312A1 (en) 2013-11-07
CN102459258B (zh) 2015-11-25
US20100311693A1 (en) 2010-12-09
CN102459258A (zh) 2012-05-16
IL216609A0 (en) 2012-02-29
KR20120044966A (ko) 2012-05-08
TWI500614B (zh) 2015-09-21

Similar Documents

Publication Publication Date Title
BRPI1009637A2 (pt) composto, composição e uso de um composto
SMP201100019B (it) Composti organici
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
EA201170772A1 (ru) Органические соединения
EA201290089A1 (ru) Химические соединения
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
BR112012030923B8 (pt) Composto derivado de piperidinona como inibidor de mdm2 e composição farmacêutica compreendendo o mesmo
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
GEP20146125B (en) Aminopyrimidines as syk inhibitors
BRPI1007622B8 (pt) Composto, composição, método não terapêutico para controlar um nematódeo parasítico e semente revestida
BRPI0915084B8 (pt) composto, e, composição farmacêutica
ECSP11010980A (es) Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
BR112012011328A2 (pt) inibidores de akt
EA201100503A1 (ru) Глюкозидные производные и их применения
BR112013002957A2 (pt) composto de 1,4,5,6-tetrahidro-pirimidin-2-ilamina
BRPI1014802B8 (pt) profármacos de triptolida.
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
JO2673B1 (en) New diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.